Oyster Point Pharma, Inc. Research and Development Expense
Oyster Point Pharma, Inc. reported Research and Development Expense of $3.91 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-11-10
- Oyster Point Pharma, Inc. research and development expense for the quarter ending 2022-09-30 was $3.91M, a 37.03% decline year-over-year.
- Oyster Point Pharma, Inc. research and development expense for the quarter ending 2022-06-30 was $4.66M, a 30.70% decline year-over-year.
- Oyster Point Pharma, Inc. research and development expense for the quarter ending 2022-03-31 was $4.68M, a 19.68% decline year-over-year.
- Oyster Point Pharma, Inc. research and development expense for the quarter ending 2021-12-31 was $5.46M, a 53.34% decline year-over-year.
- Oyster Point Pharma, Inc. research and development expense for fiscal 2021 was $24.23M, a 39.13% decline from fiscal 2020.
- Oyster Point Pharma, Inc. research and development expense for fiscal 2020 was $39.81M, a 18.39% increase from fiscal 2019.
- Oyster Point Pharma, Inc. research and development expense for fiscal 2019 was $33.63M, a 144.48% increase from fiscal 2018.
- Oyster Point Pharma, Inc. research and development expense for fiscal 2018 was $13.76M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-09-30 | $3.91M 10-Q · filed 2022-11-10 | $8.58M derived: sum of 2 quarters · filed 2022-11-10 | $13.26M 10-Q · filed 2022-11-10 | $18.72M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | $4.66M 10-Q · filed 2022-08-11 | $9.35M 10-Q · filed 2022-08-11 | $14.81M derived: sum of 3 quarters · filed 2022-08-11 | $21.02M derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-03-31 | $4.68M 10-Q · filed 2022-05-05 | $10.14M derived: sum of 2 quarters · filed 2022-05-05 | $16.36M derived: sum of 3 quarters · filed 2022-11-10 | $23.09M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-12-31 | $5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $11.68M derived: sum of 2 quarters · filed 2022-11-10 | $18.41M derived: sum of 3 quarters · filed 2022-11-10 | $24.23M 10-K · filed 2022-02-24 |
| 2021-09-30 | $6.21M 10-Q · filed 2022-11-10 | $12.94M derived: sum of 2 quarters · filed 2022-11-10 | $18.77M 10-Q · filed 2022-11-10 | $30.48M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $6.73M 10-Q · filed 2022-08-11 | $12.56M 10-Q · filed 2022-08-11 | $24.27M derived: sum of 3 quarters · filed 2022-08-11 | $32.48M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $5.83M 10-Q · filed 2022-05-05 | $17.54M derived: sum of 2 quarters · filed 2022-05-05 | $25.75M derived: sum of 3 quarters · filed 2022-05-05 | $34.30M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $11.71M 10-K · filed 2021-02-18 | $19.92M derived: sum of 2 quarters · filed 2021-11-04 | $28.47M derived: sum of 3 quarters · filed 2021-11-04 | $39.81M 10-K · filed 2022-02-24 |
| 2020-09-30 | $8.21M 10-Q · filed 2021-11-04 | $16.76M derived: sum of 2 quarters · filed 2021-11-04 | $28.10M 10-Q · filed 2021-11-04 | $43.14M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $8.55M 10-Q · filed 2021-08-05 | $19.89M 10-Q · filed 2021-08-05 | $34.93M derived: sum of 3 quarters · filed 2021-08-05 | $43.02M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $11.34M 10-Q · filed 2021-05-06 | $26.37M derived: sum of 2 quarters · filed 2021-05-06 | $34.46M derived: sum of 3 quarters · filed 2021-05-06 | $42.56M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $15.03M 10-K · filed 2021-02-18 | $23.12M derived: sum of 2 quarters · filed 2021-02-18 | $31.22M derived: sum of 3 quarters · filed 2021-02-18 | $33.63M 10-K · filed 2021-02-18 |
| 2019-09-30 | $8.09M 10-K · filed 2021-02-18 | $16.19M derived: sum of 2 quarters · filed 2021-02-18 | $18.59M 10-Q · filed 2020-11-05 | $21.94M derived: sum of 4 quarters · filed 2021-02-18 |
| 2019-06-30 | $8.10M 10-K · filed 2021-02-18 | $10.51M 10-Q · filed 2020-08-05 | $13.85M derived: sum of 3 quarters · filed 2021-02-18 | $19.63M derived: sum of 4 quarters · filed 2021-02-18 |
| 2019-03-31 | $2.40M 10-K · filed 2021-02-18 | $5.75M derived: sum of 2 quarters · filed 2021-02-18 | $11.53M derived: sum of 3 quarters · filed 2021-02-18 | $13.79M derived: sum of 4 quarters · filed 2021-02-18 |
| 2018-12-31 | $3.35M 10-K · filed 2020-02-27 | $9.12M derived: sum of 2 quarters · filed 2020-02-27 | $11.38M derived: sum of 3 quarters · filed 2020-02-27 | $13.76M 10-K · filed 2020-02-27 |
| 2018-09-30 | $5.78M 10-K · filed 2020-02-27 | $8.04M derived: sum of 2 quarters · filed 2020-02-27 | $10.41M 10-Q · filed 2019-12-03 | |
| 2018-06-30 | $2.26M 10-K · filed 2020-02-27 | $4.63M derived: sum of 2 quarters · filed 2020-02-27 | ||
| 2018-03-31 | $2.37M 10-K · filed 2020-02-27 |